Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- PMDA to Boost Workforce to 1,065 in Five Years
April 2, 2014
- MHLW to Set Up Council on Measures Against Counterfeit Drugs with Lifting of Ban on Online OTC Drug Sales
April 2, 2014
- PMDA to Conduct Pharmacokinetic Analysis in Pilot Study on Electronic NDA Submissions
April 1, 2014
- Lower House Panels to Begin Deliberations on Japanese NIH-Related Bills
April 1, 2014
- PMDA Announces Results of Pilot Study on Electronic NDA Submissions Using CDISC Standards
April 1, 2014
- Mixed Care to Be Boosted in Tokyo, Kansai Special Economic Zones: Panel
March 31, 2014
- Govt Deregulation Panel Pushes New System to Allow Mixed Care at Patient Request
March 31, 2014
- MHLW to Set Up Study Group on Clinical Research Legislation in April: Minister Tamura
March 31, 2014
- Science Council of Japan Recommends Establishment of Clinical Research Promotion Center at PMDA
March 31, 2014
- Fulminant Hepatitis Added to Precautions Section of Package Insert for Regorafenib: MHLW Safety Information
March 31, 2014
- MHLW Panel Concludes Novartis Systematically Involved in Diovan Trials: Report
March 28, 2014
- Drug-Induced Hypersensitivity Syndrome to Be Added to List of Clinically Significant Adverse Reactions for E Keppra: MHLW
March 28, 2014
- FY2014 Medical Fee Revision Expected to Shift Outpatient Care Functions from Large Hospitals to Smaller Hospitals and Clinics, Alter Patient Behavior and Prescription Patterns
March 28, 2014
- PMDA Floats New Advisory Service on Drug Makers’ Development Plans
March 27, 2014
- PMDA Announces Increase in Face-to-Face Consultation Fees in Response to Upcoming Hike in Consumption Tax
March 27, 2014
- PMDA Publishes RMP for Regpara
March 27, 2014
- Dr Tatsuya Kondo Reappointed as Chief Executive of PMDA
March 26, 2014
- MHLW Approves 37 Products, 4 New SGLT-2 Products OK’ed
March 25, 2014
- MHLW to Disclose Names of Wholesalers Abusing Penalty for Low Price-Settlement Rates
March 25, 2014
- Extra Market Drug Price Survey Focal Point of Discussions towards FY2015 Tax Hike: Official
March 20, 2014
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…